Related Experiment Video

Updated: May 11, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Emerging molecular-targeted therapies in early-phase clinical trials and preclinical models

Michael Ferguson1, Pooja Hingorani, Abha A Gupta

  • 1From the Department of Hematology/Oncology, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN; Division of Hematology Oncology, Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ; Division of Hematology/Oncology, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 30, 2013
PubMed

Insights

Standard chemotherapy has not improved survival for rhabdomyosarcoma (RMS) patients. Novel targeted therapies are needed, but research into specific molecular drivers and clinical trial inclusion remains limited.

Area of Science:

  • Pediatric Oncology
  • Cancer Therapeutics
  • Molecular Oncology

Background:

  • Standard cytotoxic chemotherapy has shown limited efficacy in improving survival for rhabdomyosarcoma (RMS) patients over the past three decades.
  • Identifying novel therapeutic targets is crucial for newly diagnosed pediatric and adolescent RMS cases.
  • Current understanding of molecular drivers, including FOXO1 translocations and translocation-negative tumors, remains incomplete.

Purpose of the Study:

  • To explore the potential of novel targeted anticancer agents for RMS treatment.
  • To review existing preclinical and clinical data on specific targeted therapies.
  • To identify challenges and limitations hindering the clinical trial inclusion of these agents.

Main Methods:

  • Review of preclinical and clinical data for targeted therapies.
  • Discussion of agents including sorafenib, pazopanib, crizotinib, TH-302, aurora-kinase inhibitors, and ALK/c-MET inhibitors.
  • Analysis of scientific and regulatory barriers to clinical trial integration.

Main Results:

  • Several targeted therapies show promise for RMS, including multi-kinase inhibitors and specific pathway inhibitors.
  • Data on the efficacy and safety of these agents in RMS is still emerging.
  • Significant scientific and regulatory hurdles impede the widespread clinical investigation of these novel agents.

Conclusions:

  • Targeted therapies represent a promising avenue for improving RMS outcomes.
  • Further research is needed to elucidate specific molecular targets and overcome clinical trial barriers.
  • Developing effective targeted treatment strategies requires a comprehensive understanding of RMS biology and rigorous clinical evaluation.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...